RecruitingNCT05762991

Application of Artificial Intelligence on the Diagnosis of Helicobacter Pylori Infection and Premalignant Gastric Lesion

Application of Artificial Intelligence on the Diagnosis of Helicobacter Pylori Infection and Premalignant Gastric Lesion: A Randomized Clinical Trial


Sponsor

National Taiwan University Hospital

Enrollment

6,000 participants

Start Date

Dec 24, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

The aim of this study is to evaluate the impact of artificial intelligence (AI) assistance during routine upper endoscopy on gastric cancer-specific mortality. We hypothesize that AI-assisted endoscopic interpretation can further reduce gastric cancer-related mortality through two mechanisms: (1) improved detection of H. pylori infection, facilitating timely eradication therapy and subsequent prevention of gastric carcinogenesis; and (2) earlier identification of premalignant gastric conditions, enabling appropriate surveillance endoscopy and earlier detection of gastric cancer. The primary endpoint is gastric cancer-specific mortality.


Eligibility

Min Age: 20 YearsMax Age: 80 Years

Inclusion Criteria2

  • Age 20-80
  • Scheduled endoscopy

Exclusion Criteria1

  • \. History of gastric surgery

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERRoutine endoscopy with artificial intelligence-assisted interpretation

(1) Improved detection of H. pylori infection, leading to timely eradication therapy. (2) Earlier identification of premalignant gastric conditions, facilitating appropriate surveillance endoscopy.


Locations(1)

Yi-Chia Lee

Taipei, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05762991


Related Trials